Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Studying Health Outcomes after Treatment in Patients with Retinoblastoma, RIVERBOAT Study

Multiple Cancer Types

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma.

Disease Sites: Pediatrics, Retinoblastoma (Pediatrics)

Phase: N/A

Investigator: Friedman, Debra

NCTID: NCT03932786

Protocol No: VICCPED1878

Learn More

A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma

This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.

Disease Sites: Not Available

Phase: III

Investigator: Esbenshade, Adam

NCTID: NCT04576117

Protocol No: COGACNS1931

Learn More

Vincristine Pharmacokinetics in Infants

Pediatrics

This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence. The dose of most anticancer drugs is adjusted to BSA, which is calculated from a patients weight and height. However, infants and young children have more severe side effects if the BSA is used to calculate their dose, so new dosing models have to be made to safely give anticancer drugs to the youngest patients. This new method uses a BSA-banded approach to determine the dose. Collecting blood samples before and after a dose of the drug will help researchers determine whether this new vincristine dosing method results in equivalent drug levels in the blood over time in infants and young children compared to older children.

Disease Sites: Pediatrics

Phase: N/A

Investigator: Borinstein, Scott

NCTID: NCT05359237

Protocol No: COGPEPN22P1

Learn More

Renal Tumors Classification, Biology, and Banking Study

Multiple Cancer Types

Disease Sites: Pediatrics, Wilms / Other Kidney (Pediatrics)

Phase: N/A

Investigator: Benedetti, Daniel

NCTID: NCT00898365

Protocol No: COGAREN03B2

Learn More

A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors

Multiple Cancer Types

This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.

Disease Sites: Neuro-Oncology, Pediatrics

Phase: III

Investigator: Esbenshade, Adam

NCTID: NCT04939597

Protocol No: COGACCL2031

Learn More

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children with Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Childrens Oncology Group Study

Multiple Cancer Types

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Disease Sites: Pediatric Leukemia, Pediatric Lymphoma, Pediatrics

Phase: N/A

Investigator: Smith, Christine

NCTID: NCT04726241

Protocol No: COGAPAL2020SC

Learn More